宫癌患者接受化疗或放射治疗的多生物标志物小组的预后价值和早期反应分层
1Department of Gynecology, Pingxiang Maternal and Child Health Hospital, Pingxiang, Jiangxi, China.
Frontiers in oncology
|November 17, 2025
概括
一个多生物标志物小组可以预测接受化疗或放射治疗的宫癌患者的治疗反应和生存结果. 这种方法有助于个性化治疗的风险分层和改善患者预后.
科学领域:
- 在瘤学瘤学.
- 生物标志物 生物标志物
- 宫癌研究研究 宫癌研究
背景情况:
- 对于宫癌患者的化学放射治疗 (CRT) 结果有很大的差异.
- 对于风险分层和治疗优化,需要最小侵入性生物标志物.
研究的目的:
- 评估一个多生物标志物小组,以预测接受CRT的局部晚期宫癌患者的早期治疗反应和长期生存.
主要方法:
- 164名FIGO IB-IVA宫癌患者接受CRT和支臂治疗被前性招募.
- 分析了基线血液标志物 (SCC-Ag,CA125,IL-6,CRP,NLR/PLR) 和HPV亚型.
- 治疗反应,无进展生存期 (PFS) 和整体生存期 (OS) 在36个月内进行了评估.
主要成果:
- 增加的SCC-Ag,CA125,IL-6,CRP和NLR/PLR与晚期疾病和较差的治疗反应相关.
- 87.1%的患者在3个月后实现了完全或部分反应.
- 通过生物标志物识别的高风险患者的PFS (58.1%) 和OS (64.5%) 与低风险患者相比显著降低,无论阶段如何.
结论:
- 一个多生物标志物小组有效地区分早期治疗反应,并预测子宫癌的存活率.
- 这个小组可以帮助个性化治疗和改善结果.
- 建议进行进一步的多机构研究来验证小组,并探索额外的标记.
更多相关视频
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...


